LENZ rallies presbyopia awareness with eyecare professionals ahead of FDA submission
2024-04-05
临床3期
LENZ Therapeutics is clear on the benefits of pre-commercial marketing for its presbyopia eye drops, bolstered by positive Phase 3 news this week. The new
data
back its confidence — and plans to file for FDA approval midyear — in its late-stage candidate and mainstream market potential.
The biotech soft-launched a campaign for eye care professionals in February, and will fully launch mid-month with the addition of 30 more optometry and ophthalmology experts joining the “Eye Am” effort. The awareness
website
uses striking photographs of leading eye care doctors taken by commercial photographer and director Will Strawser, along with statements about the doctors’ excitement and expectations around new presbyopia research.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-药物
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。